Instrument NameMedexus Pharmaceuticals IncInstrument Symbol(MDP-T)

Instrument ExchangeTSX

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 18, 2024) - Earlier in November 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) successfully completed a negotiation process with the pan-Canadian Pharmaceutical Alliance seeking to make Trecondyv® (treosulfan for injection) accessible to publicly funded drug programs and patients in Canada. The pCPA...

Fiscal Q2 2025 revenue of $26.3 million, net income of $0.1 million, operating income of $1.6 million, and Adjusted EBITDA* of $6.0 millionManagement to host conference call at 8:00 AM Eastern time on Friday, November 8, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 7, 2024) - Medexus Pharmaceuticals (TSX:...

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 29, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, November 8, 2024 to discuss Medexus's results for its second fiscal quarter ended September 30, 2024. Medexus expects to file...

Medexus Pharma is now ranked among the top 10 undervalued stocks in the Drug Manufacturers industry on the Toronto Stock Exchange or TSX Venture Exchange. A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of...

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 19, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 7, 2024 as directors through the next annual meeting. Shareholders also voted...

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 16, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the US Food and Drug Administration has extended the review period for the New Drug Application for treosulfan by three...

Medexus Pharma is now ranked among the top 10 undervalued stocks in the Drug Manufacturers industry on the Toronto Stock Exchange or TSX Venture Exchange. A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of...

Medexus Pharmaceuticals Inc is among the group of Toronto Stock Exchange stocks recently upgraded by analysts. This means each stock on this list has seen its averge consensus value move up in the last week, so at least one analyst has upgraded their view on these stocks. This report is...

Fiscal Q1 2025 revenue of $27.3 million, net income of $2.0 million, operating income of $4.0 million, and Adjusted EBITDA* of $6.1 millionManagement to host conference call at 8:00 AM Eastern time on Thursday, August 8, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 7, 2024) - Medexus Pharmaceuticals (TSX:...

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, August 8, 2024 to discuss Medexus's results for its first fiscal quarter ended June 30, 2024. Medexus expects to file...